Blinatumomab in Combination With Chemotherapy May Improve Survival in Pediatric Patients Newly Diagnosed With B-Cell Precursor ALL - report from ASH2024

Sumit Gupta, MD, PhD discusses results from the phase 3 Children’s Oncology Group Study AALL1731 presented at the 2024 ASH Annual Meeting. The study showed that adding blinatumomab to chemotherapy improved 3-year disease-free survival rates in newly diagnosed, standard risk pediatric B-cell acute lymphoblastic leukemia. Video: https://medicaldigest.org/scientific-contents/interview:blinatumomab-combination-chemotherapy-may-improve-survival-pediatric-patients-newly-diagnosed-b-cell-precursor-all